Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
2.17
-0.12 (-5.24%)
Oct 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.15 - 2.31
52 week 1.55 - 6.87
Open 2.31
Vol / Avg. 793,321.00/725,169.00
Mkt cap 191.83M
P/E     -
Div/yield     -
EPS -0.43
Shares 83.77M
Beta 2.64
Inst. own 29%
Aug 12, 2014
Q2 2014 Idera Pharmaceuticals Inc Earnings Release
Aug 12, 2014
Q2 2014 Idera Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -21863.16% -38778.72%
Operating margin -21918.42% -38657.45%
EBITD margin - -38365.96%
Return on average assets -48.01% -76.44%
Return on average equity -58.23% -228.45%
Employees 18 -
CDP Score - -

Address

167 Sidney Street
CAMBRIDGE, MA 02139
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.

Officers and directors

James A. Geraghty Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Sudhir Agrawal President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Youssef El Zein Independent Vice Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 53
Bio & Compensation  - Reuters
Louis Brenner M.D. Senior Vice President, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 48
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Director
Age: 60
Bio & Compensation  - Reuters
Kelvin M. Neu M.D. Director
Age: 41
Bio & Compensation  - Reuters
Robert W. Karr M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters